1st Quarter - Report

TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC

Firm
Client
Income
—
Expenses
$692,475
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

President Obamas Budget Proposal for FY 2013; Ryans budget

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); Health Resources & Services Administration (HRSA); Defense, Dept of (DOD); SENATE; Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of

Trade (domestic/foreign) TRD

Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; Drug Import Safety issues; foreign drug supply chain issues

LobbyistCovered position, as disclosed
DEBORAH LYNN WALTER New —
ANDREA WILKINSON —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health Resources & Services Administration (HRSA); Treasury, Dept of; Medicare Payment Advisory Commission (MedPAC); Agency for Healthcare Research & Quality (AHRQ); Defense, Dept of (DOD)

Bills named: S. 319 (112th)

Manufacturing MAN

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, U.S. and foreign supply chain and drug shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization; labeling, Best Pharmaceuticals Research Act, Pediatric Research Equity Act, Accelerated approvals, TREAT Act

LobbyistCovered position, as disclosed
DEBORAH LYNN WALTER New —
ANDREA WILKINSON —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Food & Drug Administration (FDA); Defense, Dept of (DOD); Medicare Payment Advisory Commission (MedPAC)

Bills named: H.R. 1483 (112th), S. 319 (112th), H.R. 2245 (112th)

Taxation/Internal Revenue Code TAX

Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill; Camp International Tax Reform draft; Tax Relief and Job Creation Act of 2012 (H.R. 3630);

LobbyistCovered position, as disclosed
ANDREA WILKINSON —

Contacted: Food & Drug Administration (FDA); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES; Treasury, Dept of; Agency for Healthcare Research & Quality (AHRQ); Medicare Payment Advisory Commission (MedPAC); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1206 (112th), H.R. 2190 (112th), S. 1577 (112th), H.R. 3630 (112th)

Health Issues HCR

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD, value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics,

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); SENATE; Treasury, Dept of; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Bills named: H.R. 741 (112th), S. 371 (112th)

Medicare/Medicaid MMM

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Treasury, Dept of; Health Resources & Services Administration (HRSA); Defense, Dept of (DOD); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 31 (112th), H.R. 3765 (112th), S. 1206 (112th), H.R. 3630 (112th), H.R. 457 (112th), S. 44 (112th), S. 1699 (112th), H.R. 2190 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.